These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18184092)

  • 21. Crippling HIV one mutation at a time.
    Allen TM; Altfeld M
    J Exp Med; 2008 May; 205(5):1003-7. PubMed ID: 18458116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A new veil removed from the physiologic mysteries of "HIV control" ].
    Nau JY
    Rev Med Suisse; 2007 Apr; 3(107):1017. PubMed ID: 17526378
    [No Abstract]   [Full Text] [Related]  

  • 23. Vaccines and immunology: elucidating immunity to HIV-1 and current prospects for AIDS vaccine development.
    Heeney JL; Hahn BH
    AIDS; 2000; 14 Suppl 3():S125-7. PubMed ID: 11086855
    [No Abstract]   [Full Text] [Related]  

  • 24. Vaccines for HIV--looking to the future.
    TreatmentUpdate; 2004 Oct; 16(6):1-3. PubMed ID: 17219677
    [No Abstract]   [Full Text] [Related]  

  • 25. Thinking about broadly cross-reactive vaccines.
    Doherty PC; Turner SJ
    Clin Pharmacol Ther; 2009 Jun; 85(6):665-8. PubMed ID: 19404249
    [No Abstract]   [Full Text] [Related]  

  • 26. Functional CD8+ CTLs in mucosal sites and HIV infection: moving forward toward a mucosal AIDS vaccine.
    Belyakov IM; Ahlers JD
    Trends Immunol; 2008 Nov; 29(11):574-85. PubMed ID: 18838298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AIDS vaccine test to be expanded based on upbeat results.
    AIDS Read; 2005 Nov; 15(11):561, 573. PubMed ID: 16329176
    [No Abstract]   [Full Text] [Related]  

  • 28. Rates of HIV immune escape and reversion: implications for vaccination.
    Davenport MP; Loh L; Petravic J; Kent SJ
    Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus.
    Cukalac T; Moffat JM; Venturi V; Davenport MP; Doherty PC; Turner SJ; Stambas J
    Vaccine; 2009 Nov; 27(48):6755-61. PubMed ID: 19744584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
    Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
    Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes.
    Kloverpris H; Karlsson I; Bonde J; Thorn M; Vinner L; Pedersen AE; Hentze JL; Andresen BS; Svane IM; Gerstoft J; Kronborg G; Fomsgaard A
    AIDS; 2009 Jul; 23(11):1329-40. PubMed ID: 19528789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Top stories of 2008. Crash and burn of HIV vaccine candidates.
    del Rio C
    AIDS Clin Care; 2009 Jan; 21(1):4. PubMed ID: 19219958
    [TBL] [Abstract][Full Text] [Related]  

  • 33. T cell immune responses to HIV-1.
    Vasan S; Schlesinger SJ; Arrode G
    Front Biosci; 2007 Jan; 12():2330-43. PubMed ID: 17127243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-HIV cellular immunity: recent advances towards vaccine design.
    Goulder PJ; Rowland-Jones SL; McMichael AJ; Walker BD
    AIDS; 1999; 13 Suppl A():S121-36. PubMed ID: 10885771
    [No Abstract]   [Full Text] [Related]  

  • 35. Building on the past to define an efficient path to an HIV vaccine.
    Korber B
    Expert Rev Vaccines; 2011 Jul; 10(7):929-31. PubMed ID: 21806390
    [No Abstract]   [Full Text] [Related]  

  • 36. HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation.
    McElrath MJ; Siliciano RF; Weinhold KJ
    AIDS Res Hum Retroviruses; 1997 Feb; 13(3):211-6. PubMed ID: 9115806
    [No Abstract]   [Full Text] [Related]  

  • 37. Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates.
    Mooij P; Balla-Jhagjhoorsingh SS; Koopman G; Beenhakker N; van Haaften P; Baak I; Nieuwenhuis IG; Kondova I; Wagner R; Wolf H; Gómez CE; Nájera JL; Jiménez V; Esteban M; Heeney JL
    J Virol; 2008 Mar; 82(6):2975-88. PubMed ID: 18184713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cross-clade T cell recognition of HIV.1.
    Gotch F
    Curr Opin Immunol; 1998 Aug; 10(4):388-92. PubMed ID: 9722913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV type 1 vaccine-induced cytotoxic T cell responses: potential role in vaccine efficacy.
    Ada GL; McElrath MJ
    AIDS Res Hum Retroviruses; 1997 Feb; 13(3):205-10. PubMed ID: 9115805
    [No Abstract]   [Full Text] [Related]  

  • 40. HIV-1-specific cytotoxic T-cell responses.
    Schooley RT
    AIDS; 1995; 9 Suppl A():S113-6. PubMed ID: 8819578
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.